GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Duopharma Biotech Bhd (XKLS:7148) » Definitions » EV-to-EBIT

Duopharma Biotech Bhd (XKLS:7148) EV-to-EBIT : 17.94 (As of May. 06, 2024)


View and export this data going back to 2002. Start your Free Trial

What is Duopharma Biotech Bhd EV-to-EBIT?

EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, Duopharma Biotech Bhd's Enterprise Value is RM1,451.9 Mil. Duopharma Biotech Bhd's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 was RM80.9 Mil. Therefore, Duopharma Biotech Bhd's EV-to-EBIT for today is 17.94.

The historical rank and industry rank for Duopharma Biotech Bhd's EV-to-EBIT or its related term are showing as below:

XKLS:7148' s EV-to-EBIT Range Over the Past 10 Years
Min: 6.21   Med: 14.8   Max: 39.29
Current: 17.94

During the past 13 years, the highest EV-to-EBIT of Duopharma Biotech Bhd was 39.29. The lowest was 6.21. And the median was 14.80.

XKLS:7148's EV-to-EBIT is ranked worse than
50.45% of 666 companies
in the Drug Manufacturers industry
Industry Median: 17.81 vs XKLS:7148: 17.94

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %. Duopharma Biotech Bhd's Enterprise Value for the quarter that ended in Dec. 2023 was RM1,486.1 Mil. Duopharma Biotech Bhd's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 was RM80.9 Mil. Duopharma Biotech Bhd's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Dec. 2023 was 5.45%.


Duopharma Biotech Bhd EV-to-EBIT Historical Data

The historical data trend for Duopharma Biotech Bhd's EV-to-EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Duopharma Biotech Bhd EV-to-EBIT Chart

Duopharma Biotech Bhd Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
EV-to-EBIT
Get a 7-Day Free Trial Premium Member Only Premium Member Only 14.18 30.62 20.67 19.23 18.36

Duopharma Biotech Bhd Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
EV-to-EBIT Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 19.23 18.72 16.55 17.07 18.36

Competitive Comparison of Duopharma Biotech Bhd's EV-to-EBIT

For the Drug Manufacturers - Specialty & Generic subindustry, Duopharma Biotech Bhd's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Duopharma Biotech Bhd's EV-to-EBIT Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Duopharma Biotech Bhd's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Duopharma Biotech Bhd's EV-to-EBIT falls into.



Duopharma Biotech Bhd EV-to-EBIT Calculation

Duopharma Biotech Bhd's EV-to-EBIT for today is calculated as:

EV-to-EBIT=Enterprise Value (Today)/EBIT (TTM)
=1451.916/80.948
=17.94

Duopharma Biotech Bhd's current Enterprise Value is RM1,451.9 Mil.
Duopharma Biotech Bhd's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was RM80.9 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Duopharma Biotech Bhd  (XKLS:7148) EV-to-EBIT Explanation

This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %.

Duopharma Biotech Bhd's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Dec. 2023 is calculated as:

Earnings Yield (Joel Greenblatt) % (Q: Dec. 2023 ) =EBIT / Enterprise Value (Q: Dec. 2023 )
=80.948/1486.07238
=5.45 %

Duopharma Biotech Bhd's Enterprise Value for the quarter that ended in Dec. 2023 was RM1,486.1 Mil.
Duopharma Biotech Bhd's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was RM80.9 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Duopharma Biotech Bhd EV-to-EBIT Related Terms

Thank you for viewing the detailed overview of Duopharma Biotech Bhd's EV-to-EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.


Duopharma Biotech Bhd (XKLS:7148) Business Description

Traded in Other Exchanges
N/A
Address
Lot 2599, Jalan Seruling 59, Kawasan 3, Taman Klang Jaya, Klang, MYS, 41200
Duopharma Biotech Bhd is an investment holding company engaged in manufacturing pharmaceuticals. It develops, manufactures, and markets generic and over-the-counter pharmaceutical products. The operating segment of the company is the manufacturing and distribution of pharmaceutical products. The principal activities of its subsidiary are to carry out business as a manufacturer, distributor, importer and exporter of pharmaceutical products and medicines.

Duopharma Biotech Bhd (XKLS:7148) Headlines

No Headlines